Recombinant bovine interferon (IBR)

Veterinary drug RECOMBINANT BOVINE INTERFERON (IBR)


The drug is used for the treatment and prevention of viral and bacterial-viral infections in cattle



  • A highly effective drug due to species-specific mechanism of action

  • Strengthening immune system in case of stress, overcoming the consequences of poor cattle management and imbalanced feeding

  • Antiviral, antibacterial and anti-inflammatory effect

  • Significantly enhances the biological activity of vaccines

  • Reduces the risk of postpartum uterine diseases and increases fetus preservation in pregnant cows

  • Highly effective in the prevention and treatment of bovine nodular dermatitis (skin tuberculosis, nodular rash or lumpy skin disease (LSD))

  • Eliminates the immunosuppressive effect of viruses, toxins, antibiotics

  • No complications and side effects

  • No withdrawal period for milk and meat 

Therapeutic indications:

The veterinary drug is used for the treatment and prevention of gastrointestinal and acute respiratory diseases (BRD) of viral and mixed bacterial-viral etiology in calves and adult cattle. The drug is also used as an immunostimulating agent when immunodeficiency conditions occur (poor cattle management, imbalanced feeding and so on).

Composition of the veterinary drug:

1 ml of the veterinary drug contains:

•          At least 10 000 IU of antiviral activity of recombinant bovine interferon (IBR).

Pharmacological activity:

The drug is a species-specific medicine that exhibits antiviral and immunostimulating activity in calves and adult cattle.

The active substance of the drug is a recombinant bovine protein, which belongs to the interferon group. In the animal body, interferon is mainly synthesized by cells of the immune system in response to viral infections. Interferon level determines defensive abilities of the organism, particularly in regard to weak, exhausted animals.

Recombinant bovine interferon (IBR) is a highly effective drug with species-specific mechanism of action. IBR interacts effectively with cellular receptors and exhibits antiviral and immunostimulatory activity in calves and adult cattle. The therapeutic action of the drug is determined by the multiple effect of the exogenous protein directly on the virus infected cells. The drug contributes to the rapid induction of the endogenous interferon system, cellular and humoral immunity.

The drug acts as an inducer of the serum lysozyme and bactericidal activity. Recombinant bovine interferon also has anti-inflammatory effect.  The drug increases the resistance of the animal organism to DNA and RNA-containing viruses and pathogenic microorganisms.

Dosage:

The drug is administered intramuscularly or subcutaneously at a dose of 1 ml per 10 kg of body weight.

For preventive purposes the drug is administered twice with an interval of 48 hours at a dose corresponding to the body weight of the animal:

•          in the first days after parturition,

•          in case of group housing,

•          imbalanced feeding,

•          during transportation,

•          risk of viral infections, etc.

For therapeutic purposes, the drug is used on a daily basis with an interval of 24 hours for 4 or 5 days. The drug is most effective in the early stages of disease.

The drug is administered to pregnant cows twice prior to parturition with an interval of 48 hours. In case of retarded parturition, the drug is administered again after 48 hours since the last injection.

To enhance the action of vaccines (antibacterial and inactivated viral) and sera, the drug is given as a single dose of 1 ml per 10 kg of body weight 48 hours prior to the vaccination.

In case of mixed bacterial-viral infections, the drug is given in combination with antibiotics, chemotherapeutic agents. Do not mix with antibacterial drugs in the same syringe. Do not inject in the same site with an antibacterial drug.

Precautions and adverse reactions:

When used in accordance with this instruction, side effects and complications are generally not observed.

There are no contraindications for the use of the drug.

Overdose symptoms have not been revealed.

After the first administration and cancellation no peculiarities are revealed.

Withdrawal period:

Meat and milk may be used for human consumption without any restrictions after the last drug administration. When prescribed together with antimicrobial drugs, estimate the withdrawal period for animal products in accordance with the antimicrobial drug prescriptions.

Storage conditions:

The drug should be stored in a dry, cool, dark place at a temperature between + 4 °C to + 10 °C.

The drug should be kept out of reach of children.

Shelf-life:

Shelf-life of the veterinary drug is 18 months from the date of manufacture. Shelf-life after the first opening is 28 days.

Создание сайтов в Минске - Aliva.by